Two polymorphs of a beta-lactam (trans-13-azabicyclo[10.2.0]tetradecan-14-one). Concomitant crystal polymorphism and isostructurality.

Chem Commun (Camb)

Institute of Structural Chemistry, Chemical Research Center, Hungarian Academy of Sciences, PO Box 17, Budapest 114, H-1525, Hungary.

Published: September 2004

Two polymorphs of trans-13-azabicyclo[10.2.0]tetradecan-14-one display a unique example of isostructurality, differing only in the orientation of a given hydrogen bond with respect to the beta-lactam bond. This slight difference can be attributed to the twofold rotation of the carbocyclic macroring of C2 symmetry, which in the crystal structure is hardly noticeable.

Download full-text PDF

Source
http://dx.doi.org/10.1039/b408505aDOI Listing

Publication Analysis

Top Keywords

polymorphs beta-lactam
4
beta-lactam trans-13-azabicyclo[1020]tetradecan-14-one
4
trans-13-azabicyclo[1020]tetradecan-14-one concomitant
4
concomitant crystal
4
crystal polymorphism
4
polymorphism isostructurality
4
isostructurality polymorphs
4
polymorphs trans-13-azabicyclo[1020]tetradecan-14-one
4
trans-13-azabicyclo[1020]tetradecan-14-one display
4
display unique
4

Similar Publications

Background: Systemic inflammatory indicators such as neutrophil-to-lymphocyte ratio (NLR) can effectively predict the prognosis of various inflammatory diseases. However, its prognostic effect on patients with carbapenem-resistant (CRKP) infection is little known. The objective of this study was to investigate the risk factors for mortality associated with CRKP infection and the clinical value of NLR in predicting prognosis in these patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness and safety of various antibiotic therapies for eradicating Helicobacter pylori (H. pylori) infection in children, focusing on options like triple, sequential, hybrid, concomitant, and ciprofloxacin-based therapies.
  • A randomized trial involving 200 children (ages 3-16) revealed that ciprofloxacin-based triple therapy achieved the highest eradication rate at 90%, compared to lower rates for other therapies, with no significant difference in adverse effects.
  • The conclusion highlights that ciprofloxacin-based triple therapy is the most effective and safe option for treating H. pylori infection in children, while the other treatment options do not significantly outperform traditional triple therapy.*
View Article and Find Full Text PDF

Background: Airway mucus hypersecretion (AMH) can occur in children with acute respiratory diseases, but its underlying mechanisms and relationship with the lower respiratory tract microbiota (LRTM) are not yet fully understood. This study investigates the characteristics of LRTM in children with pneumonia (MPP) and its impact on AMH.

Methods: We collected bronchoalveolar lavage fluid and related clinical indicators from 202 children with MPP.

View Article and Find Full Text PDF

Clinical outcomes and risk factors of meningitis in pediatric patients at a tertiary hospital in China.

Front Cell Infect Microbiol

September 2024

Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.

Objectives: To summarize the clinical characteristics, outcomes and identify risk factors of (AB) meningitis in children.

Methods: This was a single-center, retrospective study. Children hospitalized between January 2016 and December 2021 who were diagnosed with AB meningitis were included.

View Article and Find Full Text PDF

Carbapenem-resistant (CRKP) causes Gram-negative lung infections and fatal pneumonic sepsis for which limited therapeutic options are available. The lungs are densely innervated by nociceptor sensory neurons that mediate breathing, cough, and bronchoconstriction. The role of nociceptors in defense against Gram-negative lung pathogens is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!